All In Biotech

Drug Trial Radar · NCT04557800

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Healthy Volunteers

A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of DNL151 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Mar 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 186 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

186

Actual

Start

Nov 16, 2017

Primary completion

Feb 19, 2021

Study completion Feb 19, 2021

Sponsor

Lead sponsor
Denali Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Sep 22, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose (SAD), multiple ascending dose (MAD), and 28-day safety study of orally administered DNL151 in healthy volunteers.

Conditions

  • Healthy Volunteers

Interventions

  • DNL151Drug

    oral dose(s)

  • PlaceboDrug

    oral dose(s)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs) including serious adverse events (SAEs), and discontinuations due to TEAEsTime frame: Up to 42 days
  2. PK parameter: Maximum observed concentration (Cmax) of DNL151 in plasmaTime frame: Up to 42 days
  3. PK parameter: Time to maximum observed concentration (Tmax) of DNL151 in plasmaTime frame: Up to 42 days
  4. PK parameter: The area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞) of DNL151 in plasma (single dosing only)Time frame: Up to 42 days
  5. PK parameter: Area under the concentration-time curve from time zero to the time of last quantifiable concentration (AUC[0-last]) of DNL151 in plasmaTime frame: Up to 42 days
  6. PK parameter: The area under the concentration-time curve over a dosing interval (AUC0-τ) of DNL151 in plasma (multiple dosing only)Time frame: Up to 42 days
  7. PK parameter: Apparent terminal elimination half-life (t1/2) of DNL151 in plasmaTime frame: Up to 42 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • PRA Health Sciences, Van Swietenlaan

    Groningen, Netherlands

  • Centre for Human Drug Research

    Leiden, South Holland, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.